New Delhi: India ranks 5th out of 52 countries on the neonatal mortality rate index and bears the burden of a high neonatal mortality rate of 21.7 per 1,000 births, according to United Nations Inter-Agency Group for Child Mortality Estimation (UN IGME).
A majority of all neonatal deaths (75 per cent) occur during the first week of life. Major causes of mortality include Prematurity, Birth asphyxia, Sepsis, Pneumonia and Diarrhea. Premature babies are more prone to infections of the gut and respiratory tract which, may develop complications with long-term implications.
Now, with the development of 100 per cent human milk-based products through proprietary processing technologies, NeoLacta Lifesciences is changing the landscape of neonatal care in India.
Geetika Gangwani, Lactation Consultant emphasized that improving intact survival rates requires strengthening the quality of care as well as ensuring availability of human milk diet for all newborns. Recently, a premature baby who lost his mother soon after birth due to Covid-19 was rescued by providing pasteurised human breast milk supplied by NeoLacta Lifesciences.
Vikram Reddy, Chief Scientific Officer, NeoLacta Lifesciences says that human milk provides antibodies and is easily digestible. It contains optimal nutrients, and is gentle on the baby’s developing stomach, intestines and other body systems. Thus, it provides natural immunity for fighting infectious diseases and preventing chronic health disorders.
NeoLacta Lifesciences have introduced a range of innovative 100 per cent human milk-based products to improve the quality of nutritional care for newborns. These are pasteurised and standardised donor milk, powdered human milk for reconstitution, and a patented Mother’s Milk Fortifier. Over the last 5 years, these products are being used in over 200+ super-specialty hospitals across India.
Mothers who struggle with breastfeeding, now have an option of providing pasteurised human breast milk from NeoLacta, thereby completely avoiding bovine milk-based products such as formulas, from the baby’s diet.
While breastfeeding alone is sufficient for most infants, premature babies need a helping hand as they are at a high risk of suffering from growth deficits. NeoLact MMF (Mother’s Milk Fortifier) is a revolutionary product for feed fortification in premature and sick babies who need higher nutrient intakes to match the growth rates with their term-born peers.
Buoyed by the overwhelming response of clinicians and backed by a robust logistical network covering most metros and major cities, NeoLacta Lifesciences has embarked on a mission towards improving access to human milk through its range of 100 per cent human milk-based products, concluded Reddy.